{"id":70011,"date":"2026-07-15T12:18:48","date_gmt":"2026-07-15T04:18:48","guid":{"rendered":"https:\/\/flcube.com\/?p=70011"},"modified":"2026-07-15T12:18:49","modified_gmt":"2026-07-15T04:18:49","slug":"cspc-pharmaceutical-secures-dual-nmpa-breakthrough-therapy-designations-for-her2-positive-breast-cancer-combination","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70011","title":{"rendered":"CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>)<\/strong> announced that its <strong>self-developed docetaxel (albumin-bound) (HB1801)<\/strong> and <strong>Anbenitamab (KN026)<\/strong>\u2014developed by its subsidiary <strong>JMT-Bio<\/strong> in collaboration with <strong>Alphamab Oncology (<a href=\"https:\/\/www.google.com\/finance\/quote\/9966:HKG\">HKG: 9966<\/a>)<\/strong>\u2014have both received <strong>Breakthrough Therapy Designation<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>first-line treatment of unresectable or metastatic HER2-positive breast cancer<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Designation Type<\/strong><\/td><td>Breakthrough Therapy Designation (dual products)<\/td><\/tr><tr><td><strong>Products<\/strong><\/td><td>Docetaxel (albumin-bound) HB1801 + Anbenitamab (KN026)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer<\/td><\/tr><tr><td><strong>Development Partners<\/strong><\/td><td>CSPC Pharmaceutical (HB1801) + JMT-Bio\/Alphamab Oncology (KN026)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>14 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-portfolio-amp-strategic-integration\" class=\"wp-block-heading\">Drug Portfolio &amp; Strategic Integration<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HB1801:<\/strong> Self-developed albumin-bound docetaxel formulation by CSPC Pharmaceutical<\/li>\n\n\n\n<li><strong>Anbenitamab (KN026):<\/strong> HER2-targeting bispecific antibody developed by JMT-Bio (CSPC subsidiary) in collaboration with Alphamab Oncology<\/li>\n\n\n\n<li><strong>Combination Strategy:<\/strong> Integrated approach spanning neoadjuvant, adjuvant, and first-line advanced treatments across the entire HER2-positive breast cancer disease course<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> HB1801 Phase III trials ongoing for breast cancer and gastric cancer indications<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-positioning-comprehensive-her2-positive-breast-cancer-coverage\" class=\"wp-block-heading\">Clinical Positioning \u2013 Comprehensive HER2-Positive Breast Cancer Coverage<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Treatment Setting<\/th><th>Combination Therapy Status<\/th><th>Strategic Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Neoadjuvant<\/strong><\/td><td>Clinical positioning completed<\/td><td>Early intervention with dual-mechanism approach<\/td><\/tr><tr><td><strong>Adjuvant<\/strong><\/td><td>Clinical positioning completed<\/td><td>Post-surgical prevention of recurrence<\/td><\/tr><tr><td><strong>First-Line Advanced<\/strong><\/td><td>Breakthrough Therapy Designation granted<\/td><td>Treatment of unresectable\/metastatic disease<\/td><\/tr><tr><td><strong>Additional Indications<\/strong><\/td><td>HB1801 in Phase III for gastric cancer<\/td><td>Portfolio expansion beyond breast cancer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The combination therapy represents a comprehensive treatment strategy that addresses HER2-positive breast cancer across all major clinical settings, from early-stage to advanced metastatic disease.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-competitive-landscape\" class=\"wp-block-heading\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HER2-Positive Breast Cancer Market:<\/strong> Represents approximately 15-20% of all breast cancer cases with significant unmet need in Chinese and global markets<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> Dual Breakthrough Therapy Designation for combination therapy provides regulatory advantages and accelerated development pathway<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> CSPC&#8217;s integrated approach with proprietary chemotherapy (HB1801) combined with cutting-edge bispecific antibody (Anbenitamab) creates a differentiated treatment paradigm<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the clinical development and regulatory pathway for HB1801 and Anbenitamab. Actual results may differ due to risks including Phase III trial outcomes, final regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071400907_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026071400907_c.\"><\/object><a id=\"wp-block-file--media-fc466359-4958-4617-a8b1-13ca3412b039\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071400907_c.pdf\">2026071400907_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071400907_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-fc466359-4958-4617-a8b1-13ca3412b039\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group (HKG: 1093) announced that its self-developed docetaxel (albumin-bound) (HB1801) and Anbenitamab (KN026)\u2014developed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[187,34,171,855,854,2260],"class_list":["post-70011","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-alphamab-oncology","tag-breakthrough-therapy","tag-cspc-pharmaceutical","tag-hkg-1093","tag-hkg-9966","tag-jmt-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group (HKG: 1093) announced that its self-developed docetaxel (albumin-bound) (HB1801) and Anbenitamab (KN026)\u2014developed by its subsidiary JMT-Bio in collaboration with Alphamab Oncology (HKG: 9966)\u2014have both received Breakthrough Therapy Designation from China&#039;s National Medical Products Administration (NMPA) for first-line treatment of unresectable or metastatic HER2-positive breast cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70011\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group (HKG: 1093) announced that its self-developed docetaxel (albumin-bound) (HB1801) and Anbenitamab (KN026)\u2014developed by its subsidiary JMT-Bio in collaboration with Alphamab Oncology (HKG: 9966)\u2014have both received Breakthrough Therapy Designation from China&#039;s National Medical Products Administration (NMPA) for first-line treatment of unresectable or metastatic HER2-positive breast cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70011\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-15T04:18:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-15T04:18:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70011#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70011\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination\",\"datePublished\":\"2026-07-15T04:18:48+00:00\",\"dateModified\":\"2026-07-15T04:18:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70011\"},\"wordCount\":363,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Alphamab Oncology\",\"Breakthrough therapy\",\"CSPC Pharmaceutical\",\"HKG: 1093\",\"HKG: 9966\",\"JMT Biotechnology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70011#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70011\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70011\",\"name\":\"CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-15T04:18:48+00:00\",\"dateModified\":\"2026-07-15T04:18:49+00:00\",\"description\":\"CSPC Pharmaceutical Group (HKG: 1093) announced that its self-developed docetaxel (albumin-bound) (HB1801) and Anbenitamab (KN026)\u2014developed by its subsidiary JMT-Bio in collaboration with Alphamab Oncology (HKG: 9966)\u2014have both received Breakthrough Therapy Designation from China's National Medical Products Administration (NMPA) for first-line treatment of unresectable or metastatic HER2-positive breast cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70011#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70011\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70011#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group (HKG: 1093) announced that its self-developed docetaxel (albumin-bound) (HB1801) and Anbenitamab (KN026)\u2014developed by its subsidiary JMT-Bio in collaboration with Alphamab Oncology (HKG: 9966)\u2014have both received Breakthrough Therapy Designation from China's National Medical Products Administration (NMPA) for first-line treatment of unresectable or metastatic HER2-positive breast cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70011","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination","og_description":"CSPC Pharmaceutical Group (HKG: 1093) announced that its self-developed docetaxel (albumin-bound) (HB1801) and Anbenitamab (KN026)\u2014developed by its subsidiary JMT-Bio in collaboration with Alphamab Oncology (HKG: 9966)\u2014have both received Breakthrough Therapy Designation from China's National Medical Products Administration (NMPA) for first-line treatment of unresectable or metastatic HER2-positive breast cancer.","og_url":"https:\/\/flcube.com\/?p=70011","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-15T04:18:48+00:00","article_modified_time":"2026-07-15T04:18:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70011#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70011"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination","datePublished":"2026-07-15T04:18:48+00:00","dateModified":"2026-07-15T04:18:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70011"},"wordCount":363,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Alphamab Oncology","Breakthrough therapy","CSPC Pharmaceutical","HKG: 1093","HKG: 9966","JMT Biotechnology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70011#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70011","url":"https:\/\/flcube.com\/?p=70011","name":"CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-15T04:18:48+00:00","dateModified":"2026-07-15T04:18:49+00:00","description":"CSPC Pharmaceutical Group (HKG: 1093) announced that its self-developed docetaxel (albumin-bound) (HB1801) and Anbenitamab (KN026)\u2014developed by its subsidiary JMT-Bio in collaboration with Alphamab Oncology (HKG: 9966)\u2014have both received Breakthrough Therapy Designation from China's National Medical Products Administration (NMPA) for first-line treatment of unresectable or metastatic HER2-positive breast cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70011#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70011"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70011#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70011"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70011\/revisions"}],"predecessor-version":[{"id":70014,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70011\/revisions\/70014"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}